Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up | Zendy

Jens Lundgren | Zendy; Abdel Babiker | Zendy; Wafaa ElSadr | Zendy; Sean Emery | Zendy; Birgit Grund | Zendy; James D. Neaton | Zendy; Jacquie Neuhaus | Zendy; Andrew Phillips | Zendy

Open Access

Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up

Author(s) -

Jens Lundgren,

Abdel Babiker,

Wafaa ElSadr,

Sean Emery,

Birgit Grund,

James D. Neaton,

Jacquie Neuhaus,

Andrew Phillips

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/529523

Subject(s) - medicine , viral load , antiretroviral therapy , confidence interval , human immunodeficiency virus (hiv) , mortality rate , programmed cell death , immunology , gastroenterology , relative risk , biology , apoptosis , biochemistry

The SMART study compared 2 strategies for using antiretroviral therapy-drug conservation (DC) and viral suppression (VS)-in 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL. Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research